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The experimental procedure by which the valve cusp hypoxia (VCH) hypothesis of the etiology of deep venous thrombosis (DVT)
wasconﬁrmedlendsitselftotestingofmethodsofprophylaxis.Similaranimalexperimentscouldendthepresentexclusivereliance
on statistical analysis of data from large patient cohorts to evaluate prophylactic regimes. The reduction of need for such (usually
retrospective) analyses could enable rationally-based clinical trials of prophylactic methods to be conducted more rapidly, and the
success of such trials would lead to decreased incidences of DVT-related mortality and morbidity. This paper reviews the VCH
hypothesis (“VCH thesis”, following its corroboration) and its implications for understanding DVT and its sequelae, and outlines
the experimental protocol for testing prophylactic methods. The advantages and limitations of the protocol are brieﬂy discussed.
1.Introduction
Deep venous thrombosis (DVT) is a major concern for the
management of hospital patients and a risk for the general
population because of its high incidence. Its sequelae often
lead to mortality (via pulmonary embolism (PE)) or chronic
morbidity(postthromboticsyndrome),soprophylacticmea-
sures have long been considered priorities and are the
foci of recent discussions and guidelines published on
both sides of the Atlantic [1–4]. These and many similar
papers rely on statistical analysis of data from large patient
cohorts to evaluate prophylactic regimens. They mostly
emphasize pharmacological anticoagulation (disabling of
normalhemostaticfunction),withmechanicalmethodssuch
as intermittent pneumatic compression assigned a secondary
or adjunctive role. For example, on the basis of a review of
randomized trials since 1950, the 2011 American College of
Physiciansguidelinerecommended(i)assessmentofmedical
(including stroke) patients for the risk of thromboem-
bolism, (ii) pharmacological prophylaxis with heparin or
related drug unless there is a serious risk of bleeding, and
(iii) mechanical prophylaxis with graduated compression
stockings in the event of a bleeding risk [4].
However, despite continual reﬁnements of the pharma-
ceuticalapproach,DVT/PE-relatedmortalityhasshownonly
minimal reduction during recent decades, as reviewed in,
for example, [5, 6]. The incidence of secondary (hospital-
acquired) DVT in the USA more than tripled during the
period 1989–2006, and there was a 2.5-fold increase in the
number of admissions with a primary diagnosis of PE [7].
Several recent studies have cast doubt on the prophylactic
value of anticoagulants [4, 6, 8]. A comprehensive review of
trials indicated that heparin did not reduce overall mortality,
though it decreased the incidence of PE [4], and a large trial
showed that anticoagulant prophylaxis is associated with a
risk of serious and potentially fatal bleeding and little beneﬁt
in terms of DVT/PE prophylaxis [8]. Indeed, it has been
suspected for more than half a century that heparin does
not prevent the initiation of DVT. In 1952, for instance,
summarizing the results of a series of experiments in which
intravenous ﬁbrogenesis was induced in dogs, Samuels and
Webster wrote “It appears, from these experiments, that2 Thrombosis
ﬁbrin may appear on the injured vessel walls even in cases
where the blood is rendered incoagulable by heparin” [9].
Nevertheless, anticoagulant prophylaxis remains the stan-
dard of care for patients considered at risk for DVT and its
sequelae.
Twoconnectedreasonscanbesuggestedforthisapparent
disjunction between current practice and accumulating
evidence. First, since blood coagulation occurs at some stage
during thrombogenesis (venous or otherwise), logic suggests
that anticoagulants should inhibit the process. Data at odds
with that logic are apt to be ignored because they challenge
established belief as well as practice. However, it now seems
likely that “coagulation” is not the primary event in the
generation of a venous thrombus, but rather a consequence
of the morbid pathological process within one or more valve
pockets that can lead to thrombogenesis [10, 11]. The incip-
ient conﬂict in the recent literature could be resolved if this
accountoftheetiologyofDVT,the valvecusphypoxia(VCH)
thesis, were more widely appreciated. This thesis [10, 11]i s
summarized in the following sections and its implications
are explored. Second, the crucial evidence conﬁrming the
VCH thesis was obtained from an animal experiment [12]
that lends itself to testing approaches to prophylaxis. The
results of further studies using this experimental procedure
should answer the question “Is such-and-such a prophylactic
measure eﬀective?” and end the current reliance on statistical
analysis of large bodies of patient data. In this paper we
will describe this approach to the validation of prophylactic
measures. It involves a reproducible, noninvasive method
for inducing morphologically accurate, autochthonous deep
venous thrombi in an animal model [12].
The paper is structured as follows. In Section 2 we
summarize the VCH thesis, and in Section 3 we review some
of its implications. Section 4 comprises a description of our
proposed experimental protocol. The advantages and lim-
itations of this approach are discussed in Section 5,a n d
conclusions are drawn.
2.The Etiology of DVT:The VCHThesis
Venous blood ﬂow is inﬂuenced by two main factors: vis
at e r g oresulting from the continuous entry of blood from
the capillary beds into the venules and mechanical pumping
resulting, for example, from upward pressure on the soles
of the feet during walking and from contractions of the
gastrocnemiusandotherskeletalmuscles.Whenthereislittle
or no mechanical pumping, vis a tergo dominates and the
ﬂow is continuous (laminar, streamline, nonpulsatile); when
mechanical pumping takes place, the ﬂow is discontinuous
(intermittent, pulsatile). According to the VCH thesis [10,
11] ,D V Tm a yf o l l o ww h e np a t h o l o gi c a l l yl o n gp e r i o d s( o v e r
1.5–3.0 hours) of continuous venous blood ﬂow result in
severe hypoxemia in one or more valve pockets, leading in
turn to injurious hypoxia of the valve cusp endothelium in
the depths of the pocket(s) [11]. Should a burst of discon-
tinuous ﬂow, however brief, ﬂush out the stagnant blood
from such oxygen-starved pocket(s), the next reﬁll of the
pocket will automatically carry fresh, normally oxygenated
blood from the vein lumen, containing living leukocytes
and platelets. Such newly introduced cells may instantly
marginate, settle on, and attack the lately unperfused, mori-
bund endothelium. Living phagocytes are therefore likely to
attachthemselvestothedying parietalisendotheliallayerlin-
ing the inner aspect of the valve cusp. Alternating protracted
periods of such continuous (i.e., streamline) blood ﬂow with
restored normal (i.e., discontinuous) ﬂow can progressively
build up a burgeoning thrombus comprising accumulated
dead blood cells and concomitantly generated ﬁbrin.
In more detail, the pathogenic process can be envisaged
in terms of the following steps.
(i) Normal venous blood ﬂow is associated with a four-
phase valve cycle, which was analyzed in detail by
Lurie and colleagues [13, 14]. This cycle is strongly
dependent on the pulsatility of ﬂow, which in the
lower limbs is ensured, for example, by the calf
muscle pump and the upward pressure on the soles
of the feet during walking. In simple terms, the
valve cusp leaﬂets are forced apart (opening the
valve) when the pressure caudad exceeds the pressure
cephalad and are forced together again (closing the
valve) when the converse holds. Under conditions
when the calf muscle pump does not operate and
there is no upward pressure on the soles of the
feet, venous blood ﬂow depends mostly on vis a
tergo and becomes continuous (streamline), so the
four-phase cycle ceases to operate. The valve cusp
leaﬂets remain partly open, partly closed, their tips
oscillating slightly in the streamline ﬂow owing to the
Venturi eﬀect.
(ii) Under these conditions, the blood within the valve
pockets scarcely exchanges with the luminal blood
in the vein. Instead, it circulates within the pocket,
describing two vortices: a primary vortex near the
mouth of the pocket, driven by the passing luminal
blood and the Venturi eﬀect on the cusp leaﬂet, and
a slow secondary vortex in the depths of the pocket,
driven by the primary vortex [15–17].
(iii) Respiring blood cells in this secondary vortex, and
the endothelial cells in contact with it, progressively
deplete the oxygen store of the blood trapped in
such pockets. Theoretical calculations predict [11],
and experimental measurements conﬁrm [18], that
the hypoxemia can become suﬃciently severe after
1.5–3.0 hours to injure the endothelial cells; the PO2
registeredinthecellsdeepinthepocketfellbelowthe
detection limit of the oxygen electrode (<0.14kPa)
after such a period [18]. (Since the blood ﬂowing
in the vein lumen remains oxygenated, this strongly
suggests that the valve cusp leaﬂet is eﬀectively
impermeable to oxygen.)
(iv) Although the endothelial cells in the depths of the
valve pocket can maintain themselves temporarily
by anaerobic metabolism [19], they are inevitably
aﬀected by this sustained and extreme hypoxia. In
particular, the cells on the inner (parietalis) surface
of the valve cusp leaﬂet are likely to become necroticThrombosis 3
because—unliketheveinwallendotheliallayer—they
have no blood supply from vasa venarum [20–23]. In
contrast, the endothelial cells on the circumferential
wall of the valve pocket may survive because they
receive a vasa venarum supply [20, 21] and hence
are less susceptible to oxygen depletion of the blood
in the pocket. Therefore, while they may become
hypoxic, they need not become fatally anoxic.
(v) Endothelial cells subjected to nonfatal hypoxia
undergoaconstellationofphenotypicchangeslargely
mediated by the early growth response-1 (egr-1)
gene, which is activated via elk-1 under conditions of
reduced oxygen tension. These phenotypic changes
include signals that attract leukocytes and platelets
and initiate local coagulation largely through the
activation of tissue factor [5, 11, 24–27].
(vi) If and when intermittent, discontinuous ﬂow is re-
stored, even transiently, the normal valve cycle [13,
14] resumes. The stagnant (hypoxemic) blood is
evacuated from the valve pocket and replaced by
fresh venous blood, containing living, active leuko-
cytes and platelets. Phagocytes and platelets then
marginate on and attack the necrotic parietalis en-
dothelium of the lately hypoxic valve cusp leaﬂet,
and the resulting accumulation of functioning-then-
dying leukocytes (and platelets) is accompanied, or
quickly succeeded, by ﬁbrinogenesis.
(vii) The next (and subsequent) suﬃciently sustained ep-
isodes of continuous ﬂow—once again rendering the
valve pockets hypoxemic—may kill the blood cells
that entered such valve pocket(s) during the previous
discontinuousﬂowinterludes.Continuedalternation
of continuous ﬂow with brief discontinuous episodes
may therefore result in the layered accumulation of
generations of dead cells interspersed with dense
extensionsofﬁbrin,attachedtothenecroticparietalis
endothelium of the valve cusp leaﬂet.
(viii) If and when this “protothrombus” grows suﬃciently
large to protrude from the mouth of the valve pocket
into the vein lumen, it presents an abnormal surface
on which the passing venous blood will coagulate,
leading to further growth and generation of a frank
and manifestly classically “layered” thrombus.
(ix) Such a protruding, growing thrombus is subject to
pressure from the ﬂowing venous blood, and because
it is “anchored” only to the necrotic (and hence
fragile) parietalis endothelium, it is likely to embol-
ize.
3. Some Comments on
theEtiologicalMechanism
We will describe our experimental conﬁrmation of this ac-
count of the etiology of DVT at the beginning of Section 4.
The VCH thesis treats DVT as a consequence of vas-
cular pathophysiology, not as a hematological disorder,
emphasizing macroscopic processes rather than events at the
molecular level. In other words, it is rooted in the classical
literature. For instance, Virchow [28, 29] showed that
venous thrombi form in valves, including the predominantly
monocuspid “ostial” valves [20] at vein junctions [29],
and he subsequently detailed the morphological distinctions
between venous thrombi and blood clots [30], which are
familiar to everyone who has seen a thrombus removed dur-
ing venectomy or a pulmonary embolism removed during
postmortem examination. These morphological distinctions
(the massive accumulation of white cells and the very dense
ﬁbrin deposit in the oldest part of the thrombus, and
the characteristic striations subsequently called the lines of
Zahn)werelaterconﬁrmedbyothers[31–33],andsowasthe
ﬁnding that thrombi form on valves [34, 35], speciﬁcally on
theinnerfacesofthevalvecusps[23].Anautopsystudyofleg
vein thromboses revealed that most of the small (presumably
recent)thrombiremainedseatedinthevalvepockets,though
some older thrombi were “free-ﬂoating”, probably as a result
of dehiscence from their fragile moorings on the parietalis
endothelium [36]. The VCH thesis predicted and explains all
these observations [10, 11]. The autopsy study also showed
that venous thrombi tended to form in the more distal parts
of the limbs before the more proximal parts [36]. We may
conjecture that a thrombus impairs discontinuity of ﬂow in
portions of the vein cephalad, increasing the likelihood of
further thrombogenesis.
It is well known that DVT and its sequelae can occur in
a wide variety of circumstances in medical patients, surgical
patients, and others. Indeed, many “risk factors” have been
identiﬁed [37] and have led some authorities in the ﬁeld
to suppose that DVT is “multicausal” or “multifactorial”
[38, 39]. Irrespective of circumstances, however, there is
every reason to suppose that the thrombogenic process is
always the same, as described by the VCH; for instance, all
venous thrombi (and emboli resulting from the metastasis of
venous thrombi) show the morphological features described
by Welch [32] and others, suggesting a common pathway of
formation.
Among the “risk factors” that have attracted particular
attention during the past few years, various hereditary
and acquired thrombophilias predominate. They have been
extensively reviewed [40–43] and allare supposed to increase
the likelihood of clinically signiﬁcant DVT and PE. Accord-
ing to the VCH thesis (which is not inconsistent with the
postulate that a venous thrombus grows more rapidly in a
thrombophilic patient than in one with a supposedly normal
coagulation mechanism), the patient is not necessarily at
greater risk of DVT than normal individuals: thrombophilias
are unlikely to aﬀect the risk of thrombogenesis, though they
could aﬀect the rate of thrombus growth and the probability
of embolism, and this might be thought to make their
identiﬁcation important for the management of patients.
Since thrombus growth involves the persistent deposition
and accretion of blood elements via coagulation, anticoagu-
lants are presumed by some authorities to inhibit it, though
others prefer mechanical devices for prophylaxis, oxygenat-
ing the valve pockets by ensuring discontinuous blood
ﬂow [44–46]. However, it is not clear that anticoagulants
prevent thrombus initiation. On the other hand, mechanical4 Thrombosis
prophylactic methodologies, if they ensure regular emptying
and reﬁlling of the valve pockets, should strongly inhibit
thrombogenesis according to the VCH thesis.
We will extend these remarks in the following section.
However, we do not equate “regular emptying and reﬁlling”
with “frequent emptying and reﬁlling.” According to the
VCH thesis, the blood ﬂow rate through the vein lumen is
irrelevant to thrombogenesis; therefore, the use of mechan-
ical devices to increase the laminar venous blood ﬂow rate
is fundamentally misguided, and the concept that “general
venousstasis”isresponsibleforthrombogenesisencapsulates
only part of the truth. In principle, injurious hypoxemia may
occur in valve pockets irrespective of the ﬂow rate whenever
circulation is continuous (i.e., streamline). Therefore, the
purpose of all mechanical approaches to prophylaxis should
not be simply to accelerate venous return but to ensure
emptying and reﬁlling of the valve pockets at intervals of
not more than 30–60 minutes, which should be suﬃcient to
preclude hypoxic injury to the endothelial cells [11, 12, 18].
4. A Proposed Experimental Protocol for
EvaluatingProphylacticMeasures
The VCH thesis was conﬁrmed experimentally in 1984 by
experiments on anesthetized dogs [12]. A veterinary anes-
thetist ensured that the leg muscles did not contract during
a prolonged period of immobility, so blood ﬂow in the
leg veins was continuous (streamline). As the (barbiturate)
anesthesia lightened, the leg muscles underwent sponta-
neous “clonus”—very rapid convulsive movements—which
restored discontinuous ﬂow. A further extended period of
immobility was then achieved by a second intravenous
anesthetic dose, with recurrence of the clonic leg movements
when the animals required a further injection. Subsequent
histological examination of the leg veins showed several
thrombi anchored in the valve pockets. Two points about
this experimental production of venous thrombi must be
emphasized: (1) the thrombi were induced by a noninvasive
procedure that caused no overt injury to the veins but was
conﬁned to ensuring that several hours of continuous ﬂow
were interrupted by brief (less than 5 minutes) episodes of
discontinuous ﬂow; (2) they were morphologically indis-
tinguishable from those observed clinically, that is, they
corresponded to Virchow’s [30], Welch’s [32], and Aschoﬀ’s
[33] descriptions of venous thrombi and were therefore
not “blood clots” as deﬁned by Virchow. Control animals,
which received further doses of barbiturate to sustain the
anesthesia and prevent discontinuous ﬂow episodes, showed
no thrombi and their valve pockets were unaltered.
This experimental protocol could readily be adapted to
the purpose of testing the eﬃcacy of prophylaxis. In the
simplest case, two groups of dogs or other suitable animals
wouldberequired,andsincetheobjectiveistoobtainayesor
noanswertothequestion“Doesthisapproachtoprophylaxis
prevent DVT?” the groups would not need to be large.
Both groups would receive anesthetic and muscle relaxant
as in [12], ensuring protracted continuous ﬂow in the leg
veins punctuated by brief discontinuous ﬂow episodes; one
group would not be treated but the other would receive the
selected putative prophylaxis. Histological comparison of the
leg veins of the animals at the end of the experiment should
provide the data to answer the question.
Mechanical prophylaxis could also be assessed by this
procedure. Intermittent pneumatic compression at a lower
frequency(onceortwiceanhour),andwithlesscompression
than is currently used, would expel blood trapped in
motionless VVP, thus controlling the time for which such
trapping continues unrelieved and obviating potentially
injurious VVP hypoxemia. Were that to prove eﬀective in
all cases, as the VCH thesis predicts, it would be sensible to
proceed to clinical trials. Such less-frequent artiﬁcial pulses
would be more tolerable for patients than the disturbingly
frequent ones currently used during intermittent pneumatic
compression.
The other approach, previously proposed in [11], is 5–
10-degree Trendelenburg/anti-Trendelenberg tilting of the
animal, once again at (provisionally) 30- or 60-minute
intervals, which should be suﬃcient to empty the leg vein
valve pockets by gravity and allow them to reﬁll with
fresh blood before hypoxic injury to the endothelium can
occur, notwithstanding the continuing continuity of ﬂow
like that during “relaxant” (curare-form) anesthesia. Once
again, should that prove successful, it would be sensible
to proceed to clinical trials. Slight, infrequent, end-to-end
tilting of the bed should presumably be tolerable for most
bed-bound patients, and the procedure would be unlikely to
have discomﬁting or adverse side eﬀects.
If the proposed experimental protocol is used to evaluate
the eﬃcacy of an anticoagulant, diﬀerent doses of the drug
can be tried with a view to establishing the optimum.
This approach to testing anticoagulants would have obvious
clinical value. It would also lead to further testing and pos-
sible reﬁnement of the VCH thesis, which implies (though
this is not stated explicitly in [10, 11]) that histological
examinationofthelegveinsofanticoagulant-treatedanimals
at the end of the experiment would reveal prothrombotic
nidi on the parietalis surfaces of venous valve cusps even if
no overt (macroscopically visible) thrombus were present.
Such nidi should, according to the thesis, consist mostly
of white cells. As stated in Section 3, it is implicit in the
VCH thesis that anticoagulants do not prevent the initiation
of thrombogenesis, but they are likely to retard or prevent
thrombus growth.
5. Conclusions
Recent publications [4, 6, 8]h a v er a i s e dd o u b t sa b o u t
anticoagulant prophylaxis against DVT and its sequelae, but
this still remains the standard of care, with mechanical pro-
phylaxis assigned a subordinate role. The VCH thesis would
reverse this hierarchy. Rational approaches to mechanical
prophylaxis, designed to ensure regular emptying and reﬁll-
ing of the venous valve pockets, should preclude thrombo-
genesis. Conversely, anticoagulants, though not precluding
thrombogenesis, perhaps inhibit thrombus growth after pro-
thrombotic nidi have formed.
Anticoagulant prophylaxis is not necessarily undesirable,
though the risk of major bleeding—its best-known sideThrombosis 5
eﬀect—is of practical concern [6, 7]. The objective of any
prophylactic measure should be to prevent the formation of
thrombi that can lead to locally deleterious eﬀects (e.g., post-
thrombotic syndrome) or to potentially fatal embolization.
A method that inhibits thrombus growth could meet that
objective as eﬃciently as one that prevents thrombus forma-
tion. Nevertheless, the prevention of thrombogenesis seems
aninherentlymoresatisfactoryapproachtoprophylaxisthan
inhibition of growth, provided the chosen method has no
known signiﬁcant side eﬀects.
The experimental protocol proposed here for evaluat-
ing both pharmacological (anticoagulant) and mechanical
approaches to DVT prophylaxis would be simple and
inexpensive and would curtail the time needed to collect
suﬃcient patient data for valid statistical analysis. It should
provide information justifying (or otherwise) the use of
existing prophylactic measures and establish a basis for clini-
cal trials of new approaches, leading to further elaboration of
the VCH thesis and ipso facto new insights into the etiology
of DVT.
There are obvious limitations to these proposals. Extrap-
olation from experimental animal data to clinical manage-
ment of human patients is conjectural, so careful clinical
trials would be required in the aftermath of the experiments.
Animal experiments entail ethical concerns, which would
need to be addressed. Furthermore, some approaches to
prophylaxis, such as the proposed use of vegan or Mediter-
ranean diets [6], could not be tested using this approach—
large patient cohorts would still be necessary. Nevertheless,
a method that reliably induces clinically accurate venous
thrombi in animals provides a sound basis for testing most
actual or possible approaches to prophylaxis, and because it
would be rapid and would not require retrospective analysis
of patient data, it seems reasonable to expect that it would
result in a signiﬁcant reduction in the incidence of DVT-
related mortality and morbidity.
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